Experimental CAR-T therapies developed by Cabaletta Bio and Bristol Myers Squibb have demonstrated the ability to induce complete remissions in patients suffering from severe...
Evotec SE has received a payment of $25 million from Bristol Myers Squibb to further their collaboration in neuroscience research. This payment, announced on...